Docoh
Loading...

NTLA Intellia Therapeutics

News

From Benzinga Pro
54 Biggest Movers From Yesterday
8 Dec 21
News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas
Gainers Siyata Mobile Inc. (NASDAQ: SYTA) shares jumped 66.7% to close at $4.60 on Tuesday. Siyata Mobile received $1.3 million purchase order for SD7 ruggedized devices and accessories.
36 Stocks Moving In Tuesday's Mid-Day Session
7 Dec 21
News, Penny Stocks, Small Cap, Intraday Update, Markets, Movers, Trading Ideas
Gainers Siyata Mobile Inc. (NASDAQ: SYTA) shares climbed 123.2% to $6.16. Siyata Mobile received $1.3 million purchase order for SD7 ruggedized devices and accessories.
Cathie Wood's ARK Invest Posts Fund Purchases For Wednesday, Dec. 1, 2021: ZM, TRMB, TWLO, DNA, MTLS, SGFY, NTLA, BLDE, ACHR, MKFG, ONEM, VCYT, SDGR, SURF, MASS, SLGC, SE, TOST, VLD
2 Dec 21
Hedge Funds, Trading Ideas, General
ZOOM VIDEO COMMUNICATIONS INC (ZM) - 165622 TRIMBLE INC (TRMB) - 251411 TWILIO INC (TWLO) - 92701 GINKGO BIOWORKS HOLDINGS INC (DNA) - 1480325 MATERIALISE NV (MTLS) - 45325 SIGNIFY HEALTH INC (SGFY) -
Cathie Wood's ARK Invest Posts Fund Purchases For Tuesday, Nov. 30, 2021: ZM, TWTR, HOOD, TRMB, PACB, SGFY, MTLS, VLD, BLDE, MKFG, ACHR, ZM, CND, VCYT, ONEM, SDGR, NTLA, DNA, SLGC, MASS, ARCT, SURF, TOST, IRDM
1 Dec 21
Hedge Funds, Trading Ideas, General
ZOOM VIDEO COMMUNICATIONS INC (ZM) - 161827 TWITTER INC (TWTR) - 1112372 ROBINHOOD MARKETS INC (HOOD) - 837248 TRIMBLE INC (TRMB) - 206000 PACIFIC BIOSCIENCES OF CALIFORNIA INC (PACB) - 161674 SIGNIFY HEALTH INC
Novartis Has $21B From Roche Stake Sale - Which Company Is On Its M&A Radar?
18 Nov 21
Biotech, Long Ideas, M&A, News, Health Care, Rumors, Movers, Trading Ideas, General
Cathie Wood's ARK Invest Posts Fund Purchases For Monday, Nov. 15, 2021: NTLA, TWOU, VCYT, BEAM, MTLS, PRLB, TSP, ACHR, VLD, SPLK, DIS, BFLY, SGFY, ONEM, ALLO, VERV, QSI, HOOD, DKNG, TWLO, TOST, PAG, GRMN, DDD, MKFG
16 Nov 21
Hedge Funds, Trading Ideas, General
Intellia Therapeutics (NTLA) 2U (TWOU) Veracyte (VCYT) Beam Therapeutics (BEAM) Materialise (MTLS) Proto Labs (PRLB) TuSimple Holdings (TSP) Archer Aviation (ACHR) Velo3d (VLD) Splunk (SPLK) The Walt Disney
Cathie Wood's ARK Invest Posts Fund Purchases For Wednesday, Nov. 10 2021: PLTR, VCYT, MTLS, VLD, MKFG, ALLO, NTLA, VERV, TOST
11 Nov 21
News, Hedge Funds, Trading Ideas, General
Palantir (PLTR) Veracyte (VCYT) Materialise (MTLS) Velo3D (VLD) Markforged (MKFG) Allogene (ALLO) Intellia Therapeutics (NTLA) Verve Therapeutics (VERV) Toast (TOST)
Cathie Wood's ARK Invest Posts Fund Purchases For Friday, Nov. 5, 2021: DKNG, ROKU, TDOC, SKLZ, HOOD, NTLA, EXAS, NIU, GENI, ADPT
8 Nov 21
Hedge Funds, Trading Ideas, General
DraftKings (DKNG) Roku (ROKU) Teladoc Health (TDOC) Skillz (SKLZ) Robinhood Markets (HOOD) Intellia Therapeutics (NTLA) Exact Sciences (EXAS) Niu Technologies (NIU) Genius Sports
Cathie Wood's ARK Invest Posts Fund Purchases For Thursday, Nov. 4, 2021
5 Nov 21
Hedge Funds, Trading Ideas, General
Roku (ROKU) Teladoc (TDOC) UIPath (PATH) Robinhood (HOOD) Skillz (SKLZ) Intellia Therapeutics (NTLA) Exact Sciences (EXAS) Kratos (KTOS) Niu Technologies (NIU) Blade Air Mobility (BLDE) DraftKings
Oppenheimer Maintains Perform on Intellia Therapeutics, Lowers Price Target to $145
5 Nov 21
News, Price Target, Analyst Ratings
Oppenheimer analyst Jay Olson maintains Intellia Therapeutics (NASDAQ:NTLA) with a Perform and lowers the price target from $160 to $145.
Intellia Therapeutics To Highlight Ex Vivo Genome Editing, CRISPR/Cas9 Manufacturing Advances At 2021 American Society Of Hematology Annual Meeting
5 Nov 21
News, FDA, Events
Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, today
HC Wainwright & Co. Maintains Buy on Intellia Therapeutics, Raises Price Target to $182
5 Nov 21
News, Price Target, Analyst Ratings
HC Wainwright & Co. analyst Michael King maintains Intellia Therapeutics (NASDAQ:NTLA) with a Buy and raises the price target from $171 to $182.
Cathie Wood's ARK Invest Posts Fund Purchases For Wednesday, Nov. 3, 2021
4 Nov 21
Hedge Funds, Trading Ideas, General
Zoom Video (ZM) Exact Sciences (EXAS) Twilio (TWLO) Robinhood (HOOD) UIPath (PATH) DraftKings (DKNG) Intellia Therapeutics (NTLA) Beam Therapeutics (BEAM) Teladoc (TDOC) NIU Technologies
The Daily Biotech Pulse: Merck's Oral COVID-19 Pill Authorized In UK, Novartis Cashes Out Of Roche, Chimerix Plunges On Data, Evotec IPO
4 Nov 21
Biotech, Earnings, News, Penny Stocks, Guidance, Offerings, Small Cap, FDA, IPOs, General
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck's Oral Antiviral COVID-19 Pill Authorized In UK
Intellia Therapeutics Q3 EPS $(0.97) Misses $(0.84) Estimate, Sales $7.20M Miss $8.66M Estimate
4 Nov 21
Earnings, News
Intellia Therapeutics (NASDAQ:NTLA) reported quarterly losses of $(0.97) per share which missed the analyst consensus estimate of $(0.84) by 15.48 percent. This is a 106.38 percent decrease over losses of $(0.47) per
Earnings Scheduled For November 4, 2021
4 Nov 21
Earnings, News, Pre-Market Outlook, Markets
Companies Reporting Before The Bell • DISH Network (NASDAQ:DISH) is likely to report quarterly earnings at $0.91 per share on revenue of $4.45 billion.
Cathie Wood's ARK Invest Posts Fund Purchases For Monday, Nov. 1, 2021: NTLA, BEAM, PATH, KTOS, VLD, NIU, BLDE, MKFG, ZM, GENI, EXAS, CDNA, ALLO, VERV, ARCT, ADPT, TWLO, HOOD, TOST
2 Nov 21
Hedge Funds, Trading Ideas, General
Intellia Therapeutics (NTLA) - 10,000 Beam Therapeutics (BEAM) - 10,000 UiPath (PATH) - 231,979 Kratos Defense & Security Solutions (KTOS) - 124,745 Velo3D (VLD)
Cathie Wood's ARK Invest Posts Fund Purchases For Friday, Oct. 29, 2021: NTLA, PACB, ACHR, MKFG, BLDE, FB, CDNA, DOC, EXAS, VERV, BEAM
1 Nov 21
Hedge Funds, Trading Ideas, General
Intellia Therapeutics (NTLA) - 34,200 Pacific Biosciences of California (PACB) - 119,183 Archer Aviation (ACHR) - 591,618 MarkForged Holding Corp (MKFG) - 76,612 Blade Intellia Therapeutics (NTLA) - 34,200 Pacific Biosciences of California (PACB) - 119,183
The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline
31 Oct 21
Biotech, Earnings, News, Penny Stocks, Small Cap, FDA, IPOs, Top Stories
Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected.
Cathie Wood's ARK Invest Posts Fund Purchases For Monday, Oct. 25, 2021: TWTR, ROKU, PACB, BEAM, NNDM, SNAP, LPSN, SPOT, SKLZ, PD, ARCT, SLGC, NTLA, VERV, VCYT, PATH, DKNG, HOOD, AMZN, ETSY, PAGS, MKFG, DDD, BLDE, VLD
26 Oct 21
Hedge Funds, Trading Ideas, General
Twitter (TWTR) - 103,155 Roku (ROKU) - 12,731 Pacific Biosceiences of California (PACB) - 78,058 Beam Therapeutics (BEAM) - 7,638 Nano Dimension (NNDM)

Press releases

From Benzinga Pro
Intellia Therapeutics to Highlight Ex Vivo Genome Editing and CRISPR/Cas9 Manufacturing Advances at 2021 American Society of Hematology (ASH) Annual Meeting
5 Nov 21
News, Press Releases
CAMBRIDGE, Mass., Nov. 05, 2021 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology
Intellia Therapeutics Announces Third Quarter 2021 Financial Results and Highlights Recent Company Progress
4 Nov 21
Earnings, Press Releases
Initiated dosing of Cohort 4 in the ongoing Phase 1 study of NTLA-2001; data update from completed dose-escalation (Part 1) and initiation of dose-expansion (Part 2) expected in Q1 2022Accelerated plans to evaluate
Intellia Therapeutics to Hold Conference Call to Discuss Third Quarter 2021 Earnings and Company Updates
28 Oct 21
News, Press Releases
CAMBRIDGE, Mass., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology
Thinking about trading options or stock in Quest Diagnostics, Qualtrics International, Humana, Intellia Therapeutics, or MicroStrategy?
21 Oct 21
Fintech, Opinion, Press Releases
NEW YORK, Oct. 21, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for DGX, XM, HUM, NTLA, and MSTR.
Intellia Therapeutics Receives U.S. FDA Orphan Drug Designation for NTLA-2001, an Investigational CRISPR Therapy for the Treatment of Transthyretin (ATTR) Amyloidosis
21 Oct 21
Health Care, Press Releases, General
CAMBRIDGE, Mass., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology
Intellia Therapeutics Presents Preclinical Data Demonstrating Advancements in its Broad Genome Editing Capabilities at the 2021 European Society of Gene & Cell Therapy Annual Congress
20 Oct 21
News, Health Care, Press Releases
First preclinical data demonstrating Intellia's allogeneic platform creates immune-evading T cells for therapeutic use in future cancer treatmentsDemonstrated lipid nanoparticle-based delivery as a more efficient
Intellia Therapeutics to Present New Preclinical Data Highlighting In Vivo and Ex Vivo Genome Editing Advances at 2021 European Society of Gene & Cell Therapy Annual Congress
12 Oct 21
News, Health Care, Press Releases
First data highlighting proprietary allogeneic cell engineering platform designed to overcome immune rejection for the development of therapeutic candidates to treat a variety of cancer and autoimmune diseases New data
Intellia Therapeutics Receives Authorization to Initiate Phase 1/2 Clinical Trial of NTLA-2002 for the Treatment of Hereditary Angioedema
6 Oct 21
Health Care, Press Releases
NTLA-2002 is the first single-dose genome editing therapeutic candidate designed to prevent attacks in people living with HAE to enter clinical studyNTLA-2002 is Intellia's second in vivo CRISPR genome editing
Intellia Therapeutics to Present at Chardan's 5th Annual Genetic Medicines Conference
27 Sep 21
News, Press Releases
CAMBRIDGE, Mass., Sept. 27, 2021 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology
Intellia Therapeutics Announces U.S. FDA Acceptance of Investigational New Drug Application for NTLA-5001, its CRISPR/Cas9-Engineered TCR-T Cell Candidate for Acute Myeloid Leukemia
16 Sep 21
Health Care, Press Releases, General
NTLA-5001 is Intellia's first ex vivo candidate using its proprietary cell engineering process for the treatment of cancer to enter clinical studyNTLA-5001 targets Wilms' Tumor 1 (WT1), an overexpressed intracellular